Camurus appoints Andrew McLean as Vice President Corporate Development and Senior Counsel
Lund, Sweden — 4 January 2021 — Camurus AB (NASDAQ STO: CAMX) today announces the appointment of Andrew McLean to the position of Vice President, Corporate Development and Senior Counsel, and a member of Camurus’ Management Team.
Andrew McLean brings more than 25 years of experience from work with corporate development, licensing, merger & acquisitions, and compliance in the international pharmaceutical industry. Most recently, he was General Counsel, Company Secretary & Chief Compliance Officer at Kyowa Kirin International Plc (formerly ProStrakan). Prior to this he held senior positions at Recordati and Shire Pharmaceuticals.
Andrew McLean succeeds Urban Paulsson, who leaves his current Management Team position for other engagements and will continue to serve Camurus as a consultant.
For more information
Fredrik Tiberg, President & CEO
Tel. +46 (0)46 286 46 92
Fredrik Joabsson, Chief Business Development Officer
Tel. +46 (0)70 776 17 37
Camurus is a Swedish, science-led biopharmaceutical company committed to developing and commercializing innovative, long-acting medicines for the treatment of severe and chronic conditions. New drug products with best-in-class potential are conceived based on the company’s proprietary FluidCrystal® drug delivery technologies and its extensive R&D expertise. Camurus’ clinical pipeline includes products for the treatment of cancer, endocrine diseases, pain and addiction, which are developed in-house and in collaboration with international pharmaceutical companies. The company’s shares are listed on Nasdaq Stockholm under the ticker CAMX. For more information, visit camurus.com.
The information was submitted for publication at 8:00 am CET on 4 January 2021.